The Correlation and Mechanistic Study of GGCX Gene With Prognosis in Acute Ischemic Stroke

Peking University Aerospace Center Hospital

Status: Not yet enrolling

Conditions: Acute Ischemic Stroke

Treatments: Combination Product: Usually, all enrolled patients with acute ischemic stroke will receive routine medication and/or surgical treatment according to clinical diagnosis and treatment protocols.

Study type: Observational

Funder types: Other

Identifiers

NCT07269288

2024PSPT0905100 (Other Grant/Funding Number)

2025017

Details and patient eligibility

About

This observational study aims to investigate the impact of GGCX gene mutations and GGCX levels on stroke prognosis in patients with ischemic stroke, as well as their correlation. The main issues are:

What is the relationship and potential mechanism between GGCX gene mutations and their expression levels and the composite prognosis of recurrence, death, and bleeding events in patients with ischemic stroke? Collect blood samples from enrolled ischemic stroke patients for genetic testing, and conduct follow-up visits at 3, 6, and 12 months after discharge to evaluate clinical prognosis outcomes. This will answer questions about the relationship and mechanism between GGCX gene and patient prognosis.

Enrollment: 1,500 estimated patients

Sex: All

Ages: 18 to 85 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

• Inclusion Criteria

  (1) Inclusion Criteria for Acute Ischemic Stroke Patients:

  1. Aged between 18 and 85 years.
  2. Diagnosed with ischemic stroke (in accordance with the "Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2023," including TOAST etiological/pathogenic subtypes: large-artery atherosclerosis (LAA), cardioembolism (CE), small-artery occlusion (SAO), stroke of other determined etiology (SOE), and stroke of undetermined etiology (SUE)).
  3. Acute onset, with symptoms occurring within 72 hours and being the first episode.
  4. Voluntary participation with signed informed consent.

  (2) Inclusion Criteria for Healthy Controls: 1) Healthy control population matched for age, gender, and risk factors (including personal and family history).

• Exclusion Criteria

  (1) Exclusion Criteria for Healthy Controls:

  1. Patients with cerebrovascular diseases occurring within 72 hours.
  2. Pregnant or lactating patients.

  (2) Exclusion Criteria for Acute Ischemic Stroke Patients:

  1. Other types of stroke, including hemorrhagic stroke, mixed stroke, and tumor-related stroke patients.
  2. Patients with coagulation disorders or other hematologic diseases.
  3. Patients with severe cardiovascular, pulmonary, or hepatic diseases.
  4. Renal dysfunction.
  5. Cancer patients.
  6. Patients with active gastric ulcers or gastric bleeding.
  7. Pregnant or lactating patients.

Trial design

1,500 participants in 1 patient group

Acute Ischemic Stroke Group

Description:

These subjects were acute ischemic stroke patients who had been followed up for 3-12 months after discharge.

Treatment:

Combination Product: Usually, all enrolled patients with acute ischemic stroke will receive routine medication and/or surgical treatment according to clinical diagnosis and treatment protocols.